Search results

738 results

Sorted by Date . Sort by Relevance

Guidance Remove Guidance filter
Research recommendations Remove Research recommendations filter
In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Diagnostics guidance Remove Diagnostics guidance filter

Nivolumab with ipilimumab for untreated PD-L1 mutation-positive non-small-cell lung cancer [ID1675]

In development [GID-TA10585] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]

In development [GID-TA10490] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]

In development [GID-TA10492] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]

In development [GID-TA10567] Expected publication date: 24 November 2021

Type

Technology appraisal guidance

Status

In development
Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714]

In development [GID-TA10590] Expected publication date: 19 May 2021

Type

Technology appraisal guidance

Status

In development
Liraglutide for managing obesity in people aged 12 to 17 [ID1630]

In development [GID-TA10563] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma [ID2709]

In development [GID-TA10579] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia ID1494

In development [GID-TA10424] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer [ID1665]

In development [GID-TA10550] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 1 systemic therapy [ID1684]

In development [GID-TA10580] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin lymphoma [ID1685]

In development [GID-TA10578] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596

In development [GID-TA10497] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer [ID3756]

In development [GID-TA10631] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353

In development [GID-TA10320] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]

In development [GID-TA10620] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

In development [GID-TA10489] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]

In development [GID-TA10377] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]

In development [GID-TA10259] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy ID1147

In development [GID-TA10343] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Third molars (impacted) - prophylactic removal [ID898]

In development [GID-TAG525] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

Proposed [GID-TA10453] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Dulaglutide for treating type 2 diabetes [ID1451]

Proposed [GID-TA10439] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Multiple sclerosis - sativex [ID387]

In development [GID-TAG368] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Multiple myeloma and related disorders - Freelite assays (and alternative technologies identified during scoping) for diagnosis in primary care

In development [GID-DT28] Expected publication date: TBC

Type

Diagnostics guidance

Status

In development
Transapical transcatheter mitral valve-in-valve implantation for a failed surgically-implanted mitral valve bioprosthesis

In development [GID-IPG10152] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Gosuranemab for treating progressive supranuclear palsy [ID1607]

Proposed [GID-TA10553] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cervical ripening ballon for the induction of labour in women who have previously undergone cesarean section

In development [GID-IP1131] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)

Proposed [GID-TA10306] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID3775]

In development [GID-TA10636] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700]

Proposed [GID-TA10574] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920 ]

Proposed [GID-TA10802] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]

Proposed [GID-TA10803] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after trastuzumab or a taxane [ID3909]

Proposed [GID-TA10804] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Omalizumab for treating chronic rhinosinusitis with nasal polyps [ID1650]

In development [GID-TA10558] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Tideglusib for treating congenital myotonic dystrophy type 1 [ID3915 ]

Proposed [GID-TA10791] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mitapivat for treating pyruvate kinase deficiency [ID3914 ]

Proposed [GID-TA10795] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Maribavir for treating refractory or resistant cytomegalovirus infection after transplant [ID3900]

Proposed [GID-TA10792] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tezepelumab for maintenance treatment of uncontrolled severe asthma in people aged 12 and over [ID3910]

Proposed [GID-TA10796] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Difelikefalin for treating pruritis in people having haemodialysis [ID3890 ]

Proposed [GID-TA10793] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]

Proposed [GID-TA10797] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Brolucizumab for treating diabetic macular oedema [ID3902]

Proposed [GID-TA10794] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Faricimab for treating diabetic macular oedema [ID3899]

Proposed [GID-TA10798] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Faricimab for treating wet age-related macular degeneration [ID3898 ]

Proposed [GID-TA10799] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]

Proposed [GID-TA10800] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cemiplimab for treating recurrent or metastatic cervical cancer [ID3921]

Proposed [GID-TA10801] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Anakinra for treating active Stills disease [ID1463]

In development [GID-TA10392] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]

In development [GID-TA10611] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Bulevirtide for treating chronic hepatitis D [ID3732]

In development [GID-TA10652] Expected publication date: 20 October 2021

Type

Technology appraisal guidance

Status

In development
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) [ID1585]

In development [GID-TA10538] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Non-bisphosphonates for treating osteoporosis [ID901]

In development [GID-TA10072] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development